Imprimis Pharma (IMMY) Misses Q4 EPS by 27c

Imprimis Pharma (NASDAQ: IMMY) reported Q4 EPS of ($0.53), $0.27 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $3.5 million versus the consensus estimate of $3.52 million.

For earnings history and earnings-related data on Imprimis Pharma (IMMY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c